Skip to content
Screener

Lucid Diagnostics LUCD Q2 2026 earnings

Reported August 13, 2026 · Before market open

Revenue$1.5MBeat by $46.8K
EPS-$0.06Miss by $0.00
Revenue estimate$1.4M
EPS estimate-$0.06
“We continue to advance multiple commercial priorities while awaiting a positive draft Medicare coverage policy for EsoGuard. We secured positive commercial coverage policies, accelerated engagement with the VA and major health systems, and demonstrated the long-term economic value of EsoGuard testing. Progress across these initiatives positions Lucid to capitalize on EsoGuard's significant clinical and commercial opportunity, while increasing the company's visibility and thereby expanding opportunities for broader strategic engagement.”
Lishan Aklog

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$1.7M
EPS estimate-$0.04

Financials

Q2 2026

Income statement

See full
Revenue$1.5M+26.7%
Gross profit$29.0K+107%
Operating income-$12.8M-12.4%
Net income-$11.7M-163%

Balance sheet

See full
Cash & equivalents$33.4M+7.4%
Total debt$1.4M-37.5%
Total equity$10.9M+39.0%
Total assets$38.9M+0.7%

Cash flow

See full
Operating cash flow-$11.3M-7.1%
CapEx$21.0K-16.0%
Free cash flow-$11.3M-7.0%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$185.35M+44.4%
Enterprise value$153.36M+54.1%
P/S34×+4.6×

Profitability

See full
Operating margin-930.9%-124pp
Net margin-959.8%-187pp

Returns & leverage

See full
Return on equity-556.3%+139pp
Debt / equity0.1×-0.2×
Current ratio1.3×+0.2×

FAQ

When did Lucid Diagnostics report Q2 2026 earnings?
Lucid Diagnostics (LUCD) reported Q2 2026 earnings on August 13, 2026 before market open.
What were Lucid Diagnostics's Q2 2026 revenue and EPS?
Lucid Diagnostics reported revenue of $1.5M and eps of $-0.06 for Q2 2026.
Did Lucid Diagnostics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $1.4M by $46.8K. EPS missed the consensus estimate of $-0.06 by $0.00.
How did Lucid Diagnostics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 26.7% from $1.2M a year earlier and eps grew 40.0% from $-0.10.
Where can I find Lucid Diagnostics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001493152-26-037596) and the 10-Q periodic report (0001437749-26-027335) directly on SEC EDGAR. The filing index links above go to sec.gov.